Neil Kumar Sells 34,640 Shares of BridgeBio Pharma, Inc. (NASDAQ:BBIO) Stock

BridgeBio Pharma, Inc. (NASDAQ:BBIOGet Rating) CEO Neil Kumar sold 34,640 shares of the business’s stock in a transaction dated Thursday, November 17th. The stock was sold at an average price of $9.40, for a total value of $325,616.00. Following the sale, the chief executive officer now owns 4,813,197 shares of the company’s stock, valued at approximately $45,244,051.80. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

BridgeBio Pharma Stock Performance

BridgeBio Pharma stock opened at $9.51 on Friday. The stock’s 50 day moving average price is $10.46 and its 200 day moving average price is $9.46. The firm has a market capitalization of $1.42 billion, a PE ratio of -2.83 and a beta of 0.59. BridgeBio Pharma, Inc. has a one year low of $4.98 and a one year high of $18.13.

BridgeBio Pharma (NASDAQ:BBIOGet Rating) last announced its earnings results on Thursday, November 3rd. The company reported ($0.93) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.02) by $0.09. The business had revenue of $0.34 million during the quarter, compared to analyst estimates of $6.26 million. On average, analysts forecast that BridgeBio Pharma, Inc. will post -3.89 earnings per share for the current fiscal year.

Analysts Set New Price Targets

BBIO has been the subject of a number of research reports. JPMorgan Chase & Co. decreased their target price on BridgeBio Pharma from $20.00 to $19.00 and set an “overweight” rating for the company in a report on Friday. SVB Leerink boosted their price target on BridgeBio Pharma from $27.00 to $30.00 and gave the stock an “outperform” rating in a research report on Tuesday, July 26th. Finally, Mizuho reduced their price target on BridgeBio Pharma from $25.00 to $23.00 and set a “buy” rating on the stock in a research report on Wednesday, August 24th. Five analysts have rated the stock with a buy rating, According to MarketBeat, BridgeBio Pharma has a consensus rating of “Buy” and a consensus price target of $23.00.

Hedge Funds Weigh In On BridgeBio Pharma

A number of institutional investors have recently made changes to their positions in BBIO. DekaBank Deutsche Girozentrale raised its position in shares of BridgeBio Pharma by 9.9% in the 1st quarter. DekaBank Deutsche Girozentrale now owns 39,800 shares of the company’s stock valued at $413,000 after purchasing an additional 3,600 shares in the last quarter. SG Americas Securities LLC raised its position in shares of BridgeBio Pharma by 112.3% in the 1st quarter. SG Americas Securities LLC now owns 30,134 shares of the company’s stock valued at $306,000 after purchasing an additional 15,939 shares in the last quarter. Fernwood Investment Management LLC raised its position in shares of BridgeBio Pharma by 5.5% in the 1st quarter. Fernwood Investment Management LLC now owns 172,325 shares of the company’s stock valued at $1,749,000 after purchasing an additional 8,925 shares in the last quarter. Clearstead Advisors LLC acquired a new position in shares of BridgeBio Pharma in the 1st quarter valued at approximately $40,000. Finally, Wilbanks Smith & Thomas Asset Management LLC acquired a new position in shares of BridgeBio Pharma in the 1st quarter valued at approximately $209,000. 94.25% of the stock is owned by institutional investors and hedge funds.

BridgeBio Pharma Company Profile

(Get Rating)

BridgeBio Pharma, Inc engages in the discovery, development, and delivery of various medicines for genetic diseases. The company has a pipeline of 30 development programs that include product candidates ranging from early discovery to late-stage development. Its products in development programs include AG10 and BBP-265, a small molecule stabilizer of transthyretin, or TTR that is in Phase 3 clinical trial for the treatment of TTR amyloidosis-cardiomyopathy, or ATTR-CM; BBP-831, a small molecule selective FGFR1-3 inhibitor, which is Phase 2 clinical trial to treat achondroplasia in pediatric patients; and BBP-631, an AAV5 gene transfer product candidate that is in Phase 2 clinical trial for the treatment of congenital adrenal hyperplasia, or CAH, driven by 21-hydroxylase deficiency, or 21OHD.

Read More

Receive News & Ratings for BridgeBio Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BridgeBio Pharma and related companies with MarketBeat.com's FREE daily email newsletter.